Vice President, Business Development Transaction And Corporate Strategy
CurrentMember of Corporate Leadership Team at Transcenta (HKG: 6628)
Please complete the CAPTCHA to continue
@bms.com
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Weiwei Liang is listed as Vice President Business Development; Assets cross TAs; Innovative Technologies; AI/ML; BD&L, Equity Investment, M&A at Transcenta, based in New York City Metropolitan Area, United States. AeroLeads shows a work email signal at bms.com and a matched LinkedIn profile for Weiwei Liang.
Weiwei Liang previously worked as Vice President, Business Development Transaction and Corporate Strategy at Transcenta and Senior Director Business Development at Bristol Myers Squibb. Weiwei Liang holds Mba, Finance, Product Operations Management, Quantitative Analysis from Carnegie Mellon University - Tepper School Of Business.
This section adds company-level context without repeating Weiwei Liang's masked contact details.
AeroLeads found 1 current-domain work email signal for Weiwei Liang. Compare company email patterns before reaching out.
Weiwei Liang is an adaptable business leader with a passion for innovation. Throughout his career, he has held key positions with increasing responsibility in Business Development (BD), commercial, finance, and technology functions at Bristol Myers Squibb, Novartis, Bayer, and IBM. With over 20 years of global cross-functional experience, Weiwei has excelled in forming business strategies, leading complex transactions in BD, equity investment, and mergers and acquisitions (M&A), and achieving notable sales and margin increases.Previously serving as Senior Director of BD at Bristol Myers Squibb, Weiwei is dedicated to transforming the discovery, development, and delivery of medicines and healthcare solutions, leveraging the latest groundbreaking innovations such as Artificial Intelligence (AI) and Machine Learning across all therapeutic areas and the entire healthcare value chain. He has spearheaded significant collaborations and investments, including his company's first Multimodal AI drug discovery strategic partnership, the first AI-designed biologics research and licensing collaboration, and the first digital therapeutics collaboration. Notable publicly announced transactions led by Weiwei include CHARM Tx, Tempus AI, Terray Tx, Nabla Bio and Elekta/Kaiku. Weiwei possesses experience in various transaction types, including licensing, collaboration, co-promotion, equity investment, M&A, and divestment. His expertise also spans a wide range of assets, from molecule assets (early to late stage, innovative medicines to biosimilars and generics) to medical devices, technologies, and digital therapeutics. The total value of the deals he has led exceeds USD $2 billion.Prior to his business development career, Weiwei held various key positions in commercial, strategy, portfolio management, and BD/M&A finance. In these roles, he was responsible for developing business strategies, driving the launch of new products and solutions, as well as conducting commercial assessments and financial modeling for strategic partnerships and M&A transactions. Earlier in his career, he held leadership positions in finance controlling, and received recognition/president’s award for his roles in sales/key account management. Additionally, Weiwei has served as a board director at early-stage MedTech companies.Weiwei holds an MBA from Carnegie Mellon University – Tepper School of Business and a bachelor’s degree in Electrical and Electronics Engineering (with highest distinction) from Beijing University of Technology.
Listed skills include Strategic Planning, Business Development, Mergers, Cross Functional Team Leadership, and 20 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Princeton, Us
Member of Corporate Leadership Team at Transcenta (HKG: 6628)
Lawrence Township, Nj, Us
Area of focus: global BD&L S&E and transaction lead (licensing, collaboration, investment and acquisition) of opportunities leveraging data and digital innovations (e.g. AI, ML) to enhance and transform discovery, development and delivery of medicines.Novel transactions that have been publicly announced:
Basel, Baselstadt, Ch
Division: SandozAreas of focus: lead complex BD&L deals (licensing, acquisition and divestment of NCEs, Biologics, complex generics, biosimilars, digital therapeutics in TAs incl. oncology, immunology, CNS, cardiology, endocrinology etc.) and cross functional/global teams, from deal initiation, assessment, structuring, negotiation, due diligence, contracting to deal closing.Promoted to Director
Basel, Baselstadt, Ch
Business Franchise: Immunology, Hepatology and DermatologySpecialty: Immunology, Dermatology, Transplantation, Immunology Rare Disease• US Commercial Strategy and Operations launching Multi-Blockbuster biologic Cosentyx• BD&L, Commercial Assessment and Strategic Planning• Management & Investor Relations Support
Bloomington, Mn, Us
i-Lumen Scientific is a medical technology company pioneering a new field of treatment in electrical medicine, "Neural Retinal Therapy”™, to restore eyesight to patients afflicted with dry age-related macular degeneration (AMD).
Leverkusen, North Rhine-Westphalia, De
Specialty: Radiology and Interventional, incl. health informatics. • Strategic Evaluations, BD&L and Commercial Assessment• Portfolio Management and New Product Offerings• Business Analytics and Executive Management Support
Leverkusen, North Rhine-Westphalia, De
Performance exceeding expectations in last five years. 2013 to 2014 Manager, Business Analyst2011 to 2012 Financial Product Modeling Lead2009 to 2011 Manager, Financial Planning and Analysis2006 to 2009 Senior Financial Analyst• BD&L and M&A Finance• Portfolio Management and New Product Development rationalization• Finance and Controlling (leadership team member)• Global and Regional Strategic Planning• Emerging Market Strategy
Pittsburgh, Pa, Us
• Business Development• Market Assessment • M&A and Investment Project Financials
Armonk, New York, Ny, Us
• Key Account Management, President Award for winning the largest service contract of the year• Contract Negotiation• Engineering Project Management
Quick answers generated from the profile data available on this page.
Weiwei Liang works for Transcenta.
Weiwei Liang is listed as Vice President Business Development; Assets cross TAs; Innovative Technologies; AI/ML; BD&L, Equity Investment, M&A at Transcenta.
AeroLeads has found 1 work email signal at @bms.com for Weiwei Liang at Transcenta.
Weiwei Liang is based in New York City Metropolitan Area, United States while working with Transcenta.
Weiwei Liang has worked for Transcenta, Bristol Myers Squibb, Novartis, I-Lumen Scientific, Inc., and Amerivision.
You can use AeroLeads to view verified contact signals for Weiwei Liang at Transcenta, including work email, phone, and LinkedIn data when available.
Weiwei Liang holds Mba, Finance, Product Operations Management, Quantitative Analysis from Carnegie Mellon University - Tepper School Of Business.
Weiwei Liang is listed with skills including Strategic Planning, Business Development, Mergers, Cross Functional Team Leadership, Business Analysis, Corporate Finance, Mergers And Acquisitions, and Entrepreneurship.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts